Carbutamide |
|
| Other names | Glybutamide |
|---|
| AHFS/Drugs.com | International Drug Names |
|---|
Routes of administration | Oral |
|---|
| ATC code | |
|---|
|
4-amino-N-(butylcarbamoyl)benzenesulfonamide
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
| ECHA InfoCard | 100.005.841 |
|---|
|
| Formula | C11H17N3O3S |
|---|
| Molar mass | 271.33 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
O=S(=O)(c1ccc(N)cc1)NC(=O)NCCCC
|
InChI=1S/C11H17N3O3S/c1-2-3-8-13-11(15)14-18(16,17)10-6-4-9(12)5-7-10/h4-7H,2-3,8,12H2,1H3,(H2,13,14,15) NKey:VDTNNGKXZGSZIP-UHFFFAOYSA-N N
|
N Y (what is this?) (verify) |
Carbutamide (brand name Glucidoral) is an anti-diabetic drug of the sulfonylurea class, developed by Servier.
It is classified as first-generation.[1]
It was patented in 1953 and approved for medical use in 1956.[2]
See also
- Hellmuth Kleinsorge (1920-2001) German medical doctor
References
- ^ Ballagi-Pordány G, Köszeghy A, Koltai MZ, Aranyi Z, Pogátsa G (January 1990). "Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds". Diabetes Research and Clinical Practice. 8 (2): 109–114. doi:10.1016/0168-8227(90)90020-T. PMID 2106423.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 449. ISBN 9783527607495.
Oral diabetes medication, insulins and insulin analogues, and other drugs used in diabetes (A10) |
|---|
|
|---|
| Fast-acting |
- Insulin aspart
- Insulin glulisine
- Insulin lispro
|
|---|
| Short-acting | |
|---|
| Long-acting |
- Insulin detemir#
- Insulin glargine# (+lixisenatide)
- NPH insulin
- Lente insulin‡
- Ultralente insulin‡
|
|---|
| Ultra-long-acting |
- Insulin degludec# (+insulin aspart, +liraglutide)
- Insulin efsitora†
- Insulin icodec† (+semaglutide)
|
|---|
| Inhalable | |
|---|
| Oral | |
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
Non-insulins |
|---|
| Insulin sensitizers | | Biguanides | |
|---|
| TZDs ("-glitazones") and PPAR agonists | |
|---|
| Dual PPAR agonists |
- Aleglitazar†
- Muraglitazar§
- Saroglitazar
- Tesaglitazar§
|
|---|
| Amylin analogues and DACRAs | |
|---|
|
|---|
| Secretagogues | | K+ATP | | Sulfonylureas | |
|---|
| Meglitinides ("-glinides") | |
|---|
|
|---|
| GLP-1 receptor agonists |
- Albiglutide‡
- Danuglipron†
- Dulaglutide
- Exenatide
- Liraglutide
- Lixisenatide
- Orforglipron†
- Semaglutide
- Taspoglutide†
| GLP1 poly-agonist peptides |
- Mazdutide (GLP-1/GCGR)
- Retatrutide§ (GLP-1/GIP/GCGR)
- Tirzepatide (GLP-1/GIP)
|
|---|
|
|---|
| DPP-4 inhibitors ("-gliptins") |
- Alogliptin
- Anagliptin
- Evogliptin
- Garvagliptin
- Gemigliptin
- Gosogliptin
- Linagliptin
- Melogliptin
- Omarigliptin
- Retagliptin
- Saxagliptin
- Sitagliptin
- Teneligliptin
- Trelagliptin
- Vildagliptin
|
|---|
|
|---|
| Other | | Aldose reductase inhibitors | |
|---|
| Alpha-glucosidase inhibitors | |
|---|
| SGLT2 inhibitors ("-gliflozins") |
- Canagliflozin
- Dapagliflozin
- Empagliflozin#
- Ertugliflozin
- Ipragliflozin
- Luseogliflozin
- Remogliflozin§
- Sergliflozin§
- Sotagliflozin
- Tofogliflozin†
- Velagliflozin
|
|---|
| Other | |
|---|
|
|---|
| Combinations |
- Alogliptin/metformin
- Canagliflozin/metformin
- Cagrilintide/semaglutide§
- Dapagliflozin/metformin
- Dapagliflozin/saxagliptin
- Dapagliflozin/saxagliptin/metformin
- Empagliflozin/linagliptin
- Empagliflozin/metformin
- Gemigliptin/rosuvastatin
- Glibenclamide (glyburide)/metformin
- Glimepiride/rosiglitazone
- Linagliptin/metformin
- Metformin/acarbose
- Metformin/ertugliflozin
- Metformin/evogliptin
- Metformin/gemigliptin
- Metformin/repaglinide
- Metformin/sulfonylureas
- Metformin/teneligliptin
- Phenformin/sulfonylureas
- Pioglitazone/alogliptin
- Pioglitazone/glimepiride
- Pioglitazone/metformin
- Pioglitazone/sitagliptin
- Rosiglitazone/metformin
- Saxagliptin/metformin
- Sitagliptin/dapagliflozin
- Sitagliptin/ertugliflozin
- Sitagliptin/metformin
- Sitagliptin/simvastatin
- Vildagliptin/metformin
|
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|